Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Nektar Therapeutics (NASDAQ: NKTR) closed at $27.26 up 2.14% from its previous closing price of $26.69. In other words, the price has increased by $2.14 from its previous closing price. On the day, 1.2 million shares were traded. NKTR stock price reached its highest trading level at $28.22 during the session, while it also had its lowest trading level at $26.3364.
Ratios:
For a deeper understanding of Nektar Therapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.61 and its Current Ratio is at 2.61.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 24, 2025, Reiterated its Buy rating but revised its target price to $120 from $6.50 previously.
On June 24, 2025, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $60 to $100.
Jefferies Upgraded its Hold to Buy on April 11, 2025, while the target price for the stock was maintained at $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 19 ’25 when Zalevsky Jonathan sold 10,712 shares for $0.67 per share. The transaction valued at 7,177 led to the insider holds 305,892 shares of the business.
Wilson Mark Andrew sold 9,996 shares of NKTR for $6,697 on May 19 ’25. The Chief Legal Officer now owns 314,296 shares after completing the transaction at $0.67 per share. On May 19 ’25, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 23,208 shares for $0.67 each. As a result, the insider received 15,549 and left with 1,063,693 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 518447040 and an Enterprise Value of 519272288. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.92. Its current Enterprise Value per Revenue stands at 6.93 whereas that against EBITDA is -3.786.
Stock Price History:
The Beta on a monthly basis for NKTR is 1.06, which has changed by 0.3664161 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $37.38, while it has fallen to a 52-week low of $6.48. The 50-Day Moving Average of the stock is 30.92%, while the 200-Day Moving Average is calculated to be 80.53%.
Shares Statistics:
For the past three months, NKTR has traded an average of 1.88M shares per day and 720970 over the past ten days. A total of 19.02M shares are outstanding, with a floating share count of 18.53M. Insiders hold about 2.55% of the company’s shares, while institutions hold 45.73% stake in the company. Shares short for NKTR as of 1753920000 were 1026119 with a Short Ratio of 0.55, compared to 1751241600 on 1216697. Therefore, it implies a Short% of Shares Outstanding of 1026119 and a Short% of Float of 6.0599998.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 2.0 analysts currently analyzing and rating the stock of Nektar Therapeutics (NKTR).The consensus estimate for the next quarter is -$3.55, with high estimates of -$3.41 and low estimates of -$3.68.
Analysts are recommending an EPS of between -$9.84 and -$11.59 for the fiscal current year, implying an average EPS of -$10.68. EPS for the following year is -$11.68, with 3.0 analysts recommending between -$10.67 and -$12.76.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $10.17M this quarter.It ranges from a high estimate of $13.06M to a low estimate of $6M. As of the current estimate, Nektar Therapeutics’s year-ago sales were $24.12MFor the next quarter, 8 analysts are estimating revenue of $10.59M. There is a high estimate of $12.5M for the next quarter, whereas the lowest estimate is $8.4M.
A total of 8 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $47.16M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $42.28M. In the same quarter a year ago, actual revenue was $98.43MBased on 8 analysts’ estimates, the company’s revenue will be $40.62M in the next fiscal year. The high estimate is $52M and the low estimate is $24M.
